Skip to content
The Peptide Effect
Comparison

Follistatin vs IGF-1 LR3

Follistatin and IGF-1 LR3 both promote muscle growth but through opposite strategies. Follistatin is a naturally occurring glycoprotein that binds and inhibits myostatin and activin — effectively removing the molecular brakes on muscle growth. IGF-1 LR3 is a modified insulin-like growth factor that directly stimulates muscle protein synthesis and hyperplasia by activating the IGF-1 receptor (pressing the accelerator). Follistatin is a large protein (~36 kDa) that is extremely expensive and difficult to produce, with very limited availability, while IGF-1 LR3 is more accessible. Both remain largely preclinical for muscle-building applications in humans.

Side-by-side comparison diagram of Follistatin and IGF-1 LR3 mechanisms of action
Conceptual comparison — not to scale

Head-to-Head Comparison

CriteriaFollistatinIGF-1 LR3
Primary mechanismInhibits myostatin and activin (removes negative regulators of muscle growth)Directly activates IGF-1 receptor (stimulates muscle protein synthesis and hyperplasia)
Approach to muscle growthRemoves the brake — blocks signals that limit muscle massPresses the accelerator — directly drives anabolic signaling
Molecular sizeLarge glycoprotein (~36 kDa, 288–315 amino acids depending on isoform)Modified peptide (~9.1 kDa, 83 amino acids)
Route of administrationSubcutaneous injection (poor oral bioavailability due to size)Intramuscular or subcutaneous injection
Typical dosage100–200 mcg/day (protocols vary widely; limited standardization)20–80 mcg/day, split into 1–2 injections
Half-lifeVariable by isoform — FS344 has shorter half-life, FS315 is more stable20–30 hours (extended by LR3 modification)
Effect on myostatinDirectly binds and neutralizes myostatin — primary mechanism of actionNo direct effect on myostatin signaling
Hypoglycemia riskMinimal — does not directly affect glucose/insulin signalingSignificant — directly lowers blood glucose via insulin-like activity
Animal evidence for muscle growthStrong — myostatin knockout and follistatin overexpression produce dramatic muscle hypertrophy in mice (2–3× normal muscle mass)Strong — IGF-1 LR3 infusion produces significant muscle hypertrophy in rodents independent of load
AvailabilityVery limited — expensive to manufacture, few reliable sources, quality concernsModerately available from research peptide suppliers
Approximate monthly cost$300–$1,000+ (if authentic product can be sourced)$100–$250 (research grade)
Research statusPreclinical for muscle; AAV-follistatin gene therapy in Phase 1/2 for muscular dystrophyPreclinical for muscle; clinical research for IGF-1 deficiency conditions

When to Choose Each

Choose Follistatin

Research interest in myostatin inhibition, muscular dystrophy (gene therapy context), users willing to pay premium for theoretical myostatin blockade, those concerned about hypoglycemia from IGF-1

Choose IGF-1 LR3

Direct anabolic stimulation for muscle growth, users wanting more established dosing protocols, more cost-effective muscle peptide option, those seeking hyperplasia (new muscle cells) rather than just hypertrophy

Verdict

For most users interested in muscle growth, IGF-1 LR3 is the more practical choice — it is more available, better characterized in dosing, and has a clearer mechanism for direct anabolic stimulation. Follistatin is theoretically compelling because myostatin inhibition can produce dramatic muscle growth in animal models, but the injectable peptide form is extremely expensive, difficult to authenticate, and lacks established human dosing protocols. The most promising follistatin application is in gene therapy for muscular dystrophies, where AAV-delivered follistatin has shown encouraging early clinical results. Neither should be considered a casual supplement — both carry significant unknowns for long-term human use.

References

  1. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates (2009) — PubMed
  2. AAV1.follistatin gene therapy for inclusion body myositis: Phase 1 trial results (2017) — PubMed
  3. Myostatin inhibition in muscle — a new frontier for the treatment of cachexia and muscle wasting (2013) — PubMed
  4. Insulin-like growth factor-I LR3 promotes skeletal muscle hypertrophy independent of load (2010) — PubMed
  5. Regulation of muscle growth by multiple ligands signaling through activin type II receptors (2005) — PubMed

Frequently Asked Questions

Can follistatin and IGF-1 LR3 be stacked?
In theory, the combination would address muscle growth from both directions — removing myostatin inhibition (follistatin) while directly stimulating anabolic signaling (IGF-1 LR3). However, this combination has not been studied in humans and the practical challenges are significant: follistatin authenticity and quality are difficult to verify, combined costs are very high, and the synergistic effects (and risks) are unknown. This is firmly in experimental territory.
Is most follistatin sold online actually real?
Follistatin is one of the most frequently counterfeited peptides due to its high cost and complex manufacturing. As a large glycoprotein, it requires mammalian cell expression systems to produce properly (not simple solid-phase peptide synthesis). Many products sold as follistatin are degraded, misfolded, or entirely different substances. Third-party testing via mass spectrometry is essential before use.
What is the difference between FS344 and FS315 follistatin?
FS344 and FS315 are the two main follistatin isoforms. FS344 (344 amino acids) is a precursor that gets cleaved to FS315 and FS303 in the body. FS315 is the primary circulating form with a longer half-life due to its heparin-binding domain, making it more suitable for systemic myostatin inhibition. FS303 is more tissue-specific. Most research peptide vendors sell FS344, which the body then processes into the active forms.
How does follistatin gene therapy differ from injectable follistatin?
Follistatin gene therapy uses an adeno-associated virus (AAV) vector to deliver the follistatin gene directly to muscle tissue, enabling the muscles to continuously produce follistatin locally for months to years from a single administration. This approach has shown promising results in Phase 1/2 trials for Becker muscular dystrophy and inclusion body myositis. Injectable follistatin peptide, by contrast, requires frequent dosing, has a short half-life, and achieves far lower and less sustained tissue concentrations.
Are there safer alternatives to follistatin and IGF-1 LR3 for muscle growth?
For individuals seeking growth hormone-related muscle support with a more established safety profile, peptides like ipamorelin combined with CJC-1295 offer a less aggressive approach that stimulates natural GH and IGF-1 production rather than directly supplying exogenous growth factors. MK-677 provides oral convenience for elevating IGF-1 through endogenous pathways. These options carry fewer risks than direct IGF-1 LR3 administration (no hypoglycemia concern) and are far more accessible than authentic follistatin. However, no peptide replaces the fundamentals of resistance training and nutrition for muscle growth. Consulting a healthcare provider is recommended before considering any growth-promoting compound.

Explore next

More comparisons